Uncategorized

Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer

Innovent Biologics, Inc. and AnHeart Therapeutics announce that the Center for Drug Evaluation of China’s National Medical Products Administration has accepted a second New Drug Application for taletrectinib adipate capsule, a next-generation ROS1 tyrosine kinase inhibitor.

Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer Read More »

MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma

MaaT Pharma informs on the completion of patient recruitment for the Phase 2a clinical trial1 sponsored by AP-HP2 and in collaboration with INRAE and Institut Gustave Roussy, evaluating MaaT013, the Company’s lead product candidate, in combination with immune checkpoint inhibitors, ipilimumab and nivolumab.

MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma Read More »

Scroll to Top